Sign In
Buy IRWD
$3.24
-0.0400 (-1.22%)
At Close: Jun 03, 2026
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
04:05pm, Thursday, 28'th May 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, J
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
11:10am, Thursday, 28'th May 2026
Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
10:01am, Wednesday, 27'th May 2026
[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
10:00am, Wednesday, 27'th May 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
08:17pm, Thursday, 21'st May 2026
Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, support
Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due
04:08pm, Wednesday, 13'th May 2026
Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in to
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
04:14pm, Friday, 08'th May 2026
Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmat
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
02:35pm, Friday, 08'th May 2026
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
08:21pm, Thursday, 07'th May 2026
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
09:56am, Thursday, 07'th May 2026
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.14 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) an
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and
Best 5 Small-Cap Stocks With Forward EPS Growth Above 125%
05:56pm, Monday, 13'th Apr 2026
Small-cap stocks have outperformed amid a rotation away from mega caps, despite geopolitical uncertainty and shifting interest rate expectations. Small-cap firms may benefit from the next phase of AI
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
01:16pm, Monday, 30'th Mar 2026
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.
